Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Celldex TherapeuticsCLDX +1.10%56 Days Sales Outstanding is 953.98 as of Jun. 2026, which is 1120% above its 10-year median of 78.17. GuruFocus rates CLDX with a GF Score™ of 56/100 and a GF Value™ of $2.25 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 835 Biotechnology companies, Celldex Therapeutics ranks worse than 97.01% on this metric.
Celldex Therapeutics (NAS:CLDX) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Celldex Therapeutics Days Sales Outstanding Related Terms
Celldex Therapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Celldex Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLDX vs IRON, QURE, ATAI: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Celldex Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celldex Therapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Celldex Therapeutics's Days Sales Outstanding falls into.
Celldex Therapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 953.98 mean?
Celldex Therapeutics (CLDX) has a Days Sales Outstanding of 953.98 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Celldex Therapeutics and its competitors. This is 1120% above median its historical median of 78.17. Over the past decade, Celldex Therapeutics' Days Sales Outstanding has ranged from 40.19 to 1,226.68. According to the industry distribution chart, Celldex Therapeutics ranks #810 out of 835 companies in the Biotechnology industry, placing it in the top 97%.
Is Celldex Therapeutics' Days Sales Outstanding too high?
Celldex Therapeutics' current Days Sales Outstanding of 953.98 is 1120% above median its 10-year median of 78.17. Over the past 10 years, this metric has ranged from a low of 40.19 to a high of 1,226.68. The Biotechnology industry median Days Sales Outstanding is 68.94. Celldex Therapeutics' value of 953.98 is 1283.8% above this industry median. Based on the distribution chart, Celldex Therapeutics ranks #810 out of 835 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celldex Therapeutics has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Days Sales Outstanding compare to IRON and QURE?
According to the Biotechnology industry distribution chart, Celldex Therapeutics ranks #810 out of 835 companies for Days Sales Outstanding. This places Celldex Therapeutics in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. Celldex Therapeutics' value of 953.98 is 1283.8% above this benchmark. Historically, Celldex Therapeutics' own Days Sales Outstanding has ranged from 40.19 to 1,226.68 over the past decade. While the company's 10-year median is 78.17 vs. the industry median of 68.94, Celldex Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celldex Therapeutics's current Days Sales Outstanding of 953.98 is 1283.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Celldex Therapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celldex Therapeutics's current Days Sales Outstanding is 953.98, which is 1120% above median its own 10-year median of 78.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.25, compared to a current price of $40.41 — trading 1696% above its estimated fair value. The current Days Sales Outstanding is 953.98, which is 1120% above median its 10-year median of 78.17 and 1283.8% above the Biotechnology industry median of 68.94. Celldex Therapeutics' overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current Days Sales Outstanding is 953.98 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celldex Therapeutics (CLDX) Overvalued in 2026?
Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued.
The current stock price of $40.41 is trading 1696% above its estimated GF Value™ of $2.25.
GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.
Key valuation signals for CLDX:
Days Sales Outstanding: 953.98 (1120% above median its 10-year median of 78.17)
GF Value™: $2.25 vs. price of $40.41 (1696% above fair value)
Industry Position: 1283.8% above the Biotechnology median (#810 of 835)
No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
56GF Score
Get the complete analysis for CLDX
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDX has been successfully added to your 
